Latest News for: atrophy
Edit
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy ...
Nasdaq Globe Newswire 15 Jan 2026
... its novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
Edit
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration (Form 8-K) (Ocugen Inc)
Public Technologies 15 Jan 2026
for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration · Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs ... About dAMD and Geographic Atrophy.
Edit
Spinal Muscular Atrophy Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA ...
GetNews 15 Jan 2026
Edit
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA� (nusinersen) for Spinal Muscular Atrophy
Nasdaq Globe Newswire 12 Jan 2026
Edit
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy (Biogen Inc)
Public Technologies 12 Jan 2026
BIIB) today announced the European Commission (EC) has granted marketing authorization for a high dose regimen of SPINRAZA® (nusinersen) which is comprised of 50 mg/5 mL and 28 mg/5 mL doses for the treatment of 5q spinal muscular atrophy (SMA).
Edit
'I know Jesy Nelson's pain — because my child was born with spinal muscular atrophy'
The Mirror 09 Jan 2026
Edit
As Jesy Nelson launches campaign for NHS to screen ALL newborns for spinal muscular atrophy ...
The Daily Mail 08 Jan 2026
The UK is a global outlier in relation to newborn SMA screening, which is currently in place within the United States and across most of Europe ....
Edit
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD
PR Newswire 08 Jan 2026
Food and Drug Administration (FDA) has granted Fast Track Designation for CTx001, the company's lead gene therapy candidate for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
Edit
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy ...
Canada Newswire 08 Jan 2026
Food and Drug Administration (FDA) has granted Fast Track Designation for CTx001, the company's lead gene therapy candidate for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD).
Edit
Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD (GIMV NV)
Public Technologies 08 Jan 2026
FDA Fast Track designation has been granted to CTx001 for Geographic Atrophy secondary to Age-related Macular Degeneration ... About Geographic Atrophy. Geographic Atrophy (GA) is a leading cause of ...
Edit
The Geographic Atrophy Industry: A Global and Regional Analysis 2025-2035
Nasdaq Globe Newswire 06 Jan 2026
Edit
Multiple System Atrophy Market in the 7MM is projected to grow at a CAGR of ...
GetNews 06 Jan 2026
Edit
What is Spinal Muscular Atrophy type 1 as Jesy Nelson's twins receive heartbreaking diagnosis
Daily Record 05 Jan 2026
Edit
What is spinal muscular atrophy? As Jesy Nelson shares twins’ diagnosis
The Independent 05 Jan 2026
The singer shared an emotional update about her twins’ health on Sunday. .
Edit
Spinal muscular atrophy explained after Jesy Nelson reveals her twins’ diagnosis
The Independent 05 Jan 2026
The singer shared an ...
- 1
- 2
- Next page »